The final, formatted version of the article will be published soon.
CLINICAL TRIAL article
Front. Pharmacol.
Sec. Obstetric and Pediatric Pharmacology
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1479205
Pharmacokinetics and Bioequivalence of Two Formulations of Mifepristone Tablets in Healthy Chinese Subjects under Fasting Conditions: A single-center, Open, Randomized, Single-Dose, Double-Period, Two-Sequence, Crossover Trial
Provisionally accepted- 1 Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
- 2 Wuhan Jiulong Renfu Pharmaceutical Limited Company, Wuhan, China, wuhan, China
- 3 Wuhan Hongren Biopharmaceutical Inc, Wuhan, wuhan, China
Objective: A bioequivalence (BE) study was done to evaluate the pharmacokinetics, safety, and bioequivalence of two formulations of mifepristone tablets in healthy Chinese volunteers under fasting conditions.Methods: A single-center, open, randomized, single-dose, double-period, two-sequence, crossover study in healthy subjects under fasting conditions was performed. The subjects received a single fasting dose of mifepristone (10 mg/tablet) during the first and second periods, followed by a 14-day washout period, during which frequent PK sampling occurred up to 120 hours. The pharmacokinetic parameters of mifepristone were calculated based on the plasma drug concentration-time profile. Primary endpoints were the BE of major pharmacokinetic parameters (AUC 0-t and AUC 0-∞ ) and the maximum observed serum concentration (C max ). Secondary endpoints were safety parameters.Results: Forty subjects (34 males and 6 females) were randomly assigned to treatment, of whom 39 completed the two-period study. After single administration of mifepristone tablets (test preparation vs reference preparation) under fasting conditions the GMRs of C max , AUC 0-t , AUC 0-∞ were 98.76%, 104.28% and 104.83%, respectively. The primary metabolite of mifepristone (RU42633) the GMRs of C max , AUC 0-t , AUC 0-∞ were 102.33%, 103.17% and 104.02%, respectively. The primary metabolite of mifepristone (RU42698) the GMRs of C max , AUC 0-t , AUC 0-∞ were 100.97%, 103.71% and 103.84%, respectively. All 90% confidence intervals (CIs) for the test/reference AUC ratio and Cmax ratio were within the acceptable range (80%-125%) for BE, which met the requirements of bioequivalence. No serious adverse events (AEs) occurred, and all AEs were classified as level 1 or 2.The PK parameters of mifepristone and its metabolites (RU42633 and RU42698) were measured using the geometric mean ratios (GMRs) of AUC 0-t , AUC 0-∞ and C max were similar between the test and reference drug. The two formulations of mifepristone showed good tolerability and a similar safety profile.Clinical Trial Registration: chinaDrugtrials.org.cn, identifier CTR20182413.
Keywords: Bioequivalence, Mifepristone, pharmacokinetic, Fasting condition, Chinese healthy subjects
Received: 11 Aug 2024; Accepted: 13 Sep 2024.
Copyright: © 2024 Yan, Zhu, DONG, LIN, LU, Zeng, CHEN, MENG and LIU. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yufeng Yan, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
Xiaoshan Zhu, Wuhan Jiulong Renfu Pharmaceutical Limited Company, Wuhan, China, wuhan, China
Ping DONG, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
Cheng LIN, Wuhan Jiulong Renfu Pharmaceutical Limited Company, Wuhan, China, wuhan, China
Lingqing LU, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
Guiying CHEN, Wuhan Hongren Biopharmaceutical Inc, Wuhan, wuhan, China
Xianmin MENG, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
Min LIU, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.